Next Article in Journal
CENP-A Ubiquitylation Contributes to Maintaining the Chromosomal Location of the Centromere
Previous Article in Journal
Proanthocyanidins Protect against β-Hydroxybutyrate-Induced Oxidative Damage in Bovine Endometrial Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 3
10.3390/molecules24030401
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

HMPA-Catalyzed Transfer Hydrogenation of 3-Carbonyl Pyridines and Other N-Heteroarenes with Trichlorosilane

by
Yun Fu
1,2 and
Jian Sun
1,*
1
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China
2
University of Chinese Academy of Sciences, Beijing 100049, China
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(3), 401; https://doi.org/10.3390/molecules24030401
Submission received: 22 December 2018 / Revised: 17 January 2019 / Accepted: 19 January 2019 / Published: 22 January 2019
Browse Figures
Versions Notes

Abstract

:
A method for the HMPA (hexamethylphosphoric triamide)-catalyzed metal-free transfer hydrogenation of pyridines has been developed. The functional group tolerance of the existing reaction conditions provides easy access to various piperidines with ester or ketone groups at the C-3 site. The suitability of this method for the reduction of other N-heteroarenes has also been demonstrated. Thirty-three examples of different substrates have been reduced to designed products with 45–96% yields.

Graphical Abstract

1. Introduction

Piperidines are very important structural building blocks of numerous biologically active compounds, such as the Topo inhibitor, the Chk1 inhibitor, Tiagabine and Focalin XR [1]. The catalytic hydrogenation of pyridines provides one of the most straightforward methods to access piperidines [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18], although it is essential to overcome some inherent challenges presented by catalyst deactivation and pyridine dearomatization. In the last decade, various transition-metal catalyst systems have been studied for the direct hydrogenation of pyridines, but the metal-free catalytic reduction of pyridines is a great challenge [19,20,21,22,23,24].
In recent years, frustrated Lewis base pairs have been proven as efficient catalyst systems for the regio- and chemoselective reduction of pyridines with various reducing agents. In particular, Stephan [25] and Du [26], respectively, reported the metal-free organoborane-catalyzed hydrogenation of pyridines with H2. Later on, Du [27] developed a method for the metal-free organoborane catalyzed transfer hydrogenation of pyridines with ammonia boranes. Chang [28] and Wang [29] reported the B(C6F5)3 catalyzed reduction of pyridines with Et2SiH2 and PhMe2SiH, respectively (Figure 1). For the reduction of the 3-carbonyl pyridines, Rueping reported the first example of organocatalytic transfer hydrogenation of 3-carbonyl pyridines with Hantzsch ester for the preparation of chiral 1,4-dihydropyridine (DHP) derivatives [30]. Although a variety of 3-carbonyl piperidines derivatives could be prepared with these methods, there are still some drawbacks: (1) For most of these reactions, a high temperature and (2) high pressure of H2 was required. Therefore, the search for new methods for the reduction of 3-carbonyl pyridines still remains a challenging task.
Trichlorosilane with a Lewis base as an activator is a well-known unsaturated double bond reduction method. Its strength has been well demonstrated by others and ourselves in terms of asymmetric reduction of double bonds [31,32,33,34,35,36,37,38]. However, to the best of our knowledge, the reduction of pyridines by use of this system still presents a great challenge, and no successful protocol has been reported. In our previous study, we found trichlorosilane could activate the imine substrate through coordination of the nitrogen atom. A similar coordination was also found when trichlorosilane and pyridines were added together. Thus, we envisioned that pyridines would be reduced by trichlorosilane with a proper Lewis base activator. Here in, we wish to communicate the results of our study and present a highly effective new method to reduce 3-carbonyl pyridines under an organic Lewis base activated trichlorosilane system.

2. Results and Discussion

To implement our design, phenyl(pyridin-3-yl)methanone 1a was used as a model substrate to test the catalytic activity of various commercially available Lewis bases. We found that the reduced product could be obtained with 49% and 37%, respectively, when 0.2 equivalent of HMPA (hexamethylphosphoric triamide) or POPh3 were used. However, only a trace amount of reduced product could be detected when DMF (N,N-dimethylformamide) was used, which has been proven as an efficient catalyst for the reduction of C=O and C=N bonds with trichlorosilane. Dichloromethane was the most suitable solvent for this reaction. An 86% yield could be obtained when six equivalents of trichlorosilane were added as a reducing agent. The yield could be increased further to 96% when the reaction was stirred at 25 °C for 24 h. Decreasing the amount of HMPA to 10 mol% and 5 mol%, respectively, both caused a clear drop in the yield. After a careful investigation, we identified the best reaction conditions in which the substrate 1a was reduced with trichlorosilane (6.0 equivalent) under the catalysis of HMPA (20 mol%) in DCM (dichloromethane) at 25 °C for 24 h (Table 1).
With the optimized reaction conditions in hand, the scope and limitations for the substrates were investigated. We found a series of phenyl(pyridin-3-yl)methanone derivatives could be reduced under the existing reaction conditions to get the desired product with good yields (Figure 2). The desired products 2b–2h were obtained with 62–91% yields when the phenyl group of phenyl(pyridin-3-yl)methanone was replaced with other aryl and alkyl substituents. The 3,5-disubstituted pyridines could also be reduced under the existing reaction conditions. The substituents of the 5-position of the pyridine ring could be aryl and alkyl groups. The 5-phenethyl and 5-methyl substituted substrates could be reduced to the desired products 2i and 2j with 61% and 77% yields, respectively. When the 5-position substituent groups of pyridines were Ph, 4-MePh, 4-FPh and 1-napthyl, these pyridines could be reduced to 3,5-disubsitituted piperidines with 82–88% yields. The substrates with a hetero aromatic group at the 5-position of the pyridines are also tolerated. The desired products 2o and 2p were obtained with 73% and 82% yields, respectively, when the thiopen-2-yl and thiopen-3-yl substituted substrates were reduced under the existing reaction conditions. Next, we found that the 3,6-disubstituted substrates could be reduced with moderate yields. The desired reducing products 2q–2s could be obtained with 40–53% yields.
Ethyl nicotinate and its 5-position substituted derivatives are tolerated under the existing reaction conditions. Ethyl nicotinate was reduced to the corresponding product 2t with a 75% yield. The 5-methly substituted ethyl nicotinate was reduced with a 41% yield, and the 5-Ph, 4-MeOPh and 4-FPh substituted ethyl nicotinate were reduced to their corresponding products 2v–2x with 75–76% yields. The 5-BnO substituted ethyl nicotinate could also be reduced to the corresponding product 2y with a 45% yield. In order to confirm the relative configuration of the main product, compounds 5 and 6 were synthesized according the literature, and the trans product was confirmed to be the main product [39].
Pyridine derivatives such as 3-Br, 3-CF3, 3-NO2, and 3-CN substituted pyridines could not be reduced under the existing reaction conditions. However, other N-heteroarenes such as quinoxaline (3a) and 2-phenylquinoxaline (3b) could be reduced to their tetrahydroquinoxaline derivatives 4a [29] and 4b [40] with high yields. The substrates 3c and 3d were partially reduced to the products 4c and 4d. Quinolone (3e) and isoquinoline (3f) were reduced to products 4e [41] and 4f [41], respectively, with moderate yields. 1,5-Naphthyridine (3g) and 1,10-phenanthroline (3h) could only be partially reduced to the products 4g [42] and 4h [43] (Figure 3). All attempts to achieve the fully reduced products of 3c, 3d, 3g and 3h have failed.
In order to shed light on the mechanistic pathway, in situ NMR analysis was performed. We first found that ethyl nicotinate could form a complex with HSiCl3 when the reaction was set in CDCl3 under the otherwise identical reaction conditions. An obvious chemical shift in the aromatic region could be detected when HSiCl3 was added to the solution of 1t. Besides the signals of the designed products, a group of peaks that matched the intermediate C were also detected at the beginning. The intensity of these peaks would decrease with the addition of water. At the end of the reaction, only the peaks of designed product and HMPA could be detected (Figure 4).
Based on the above observations and precedents indicating a stepwise process in the reduction of unsaturated pyridines [27], we proposed a possible mechanistic pathway for the present HMPA-catalyzed reduction of pyridines (Figure 5). The first step was assumed to be the formation of a HSiCl3 and substrate complex, followed by the hydride attack at the C-4 position to produce the 1,4-dihydropyidine intermediate, A, which will transfer to B in the presence of a proton, and then be reduced to D with HSiCl3 under the catalysis of HMPA. The D to E step is the rate-determining step, since only the intermediate D could be detected and isolated from the reaction. The proton which is coming from the hydrochloride that is formed by the hydrolysis of HSiCl3 is important for the existing reaction.
In order to illustrate the synthetic potential of these methodologies, a gram-scale reaction was carried out using 1t as the substrate. Fortunately, the desired product, 2t, was obtained in a yield of 69% (Figure 6).

3. Materials and Methods

All solvents used in the reactions were distilled from the appropriate drying agents prior to use. All substrates were analogously prepared and characterized as reported in the Supplementary Materials. Reactions were monitored by thin layer chromatography, using silica gel HSGF254 plates. Flash chromatography was performed using silica gel HG/T2354-92. 1H- and 13C-NMR (400 and 100 MHz, respectively) spectra were recorded in CDCl3. The 1H-NMR chemical shifts are reported in ppm (δ) relative to tetramethylsilane (TMS), with the solvent resonance employed as the internal standard (CDCl3, δ 7.26 ppm). Data are reported as follows: Chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, dd = double doublet), coupling constants (Hz) and integration. 13C-NMR chemical shifts are reported in ppm from tetramethylsilane (TMS) with the solvent resonance as the internal standard (CDCl3, δ 77.0 ppm). ESIMS (Electron Spray Ionization Mass Spectrometry) spectra were recorded on BioTOF Q (Bruker, Billerica, MA, USA).

3.1. Reduction of Pyridines and N-Heteroaromatics

Under an argon atmosphere, pyridine 1 or N-heteroaromatic 3 (0.10 mmol) and HMPA (3.5 mg, 0.02 mmol) were added in anhydrous DCM (0.7 mL) and stirred at room temperature for 10 min, and then trichlorosilane (2.0 M, 0.3 mL) was added. The reaction was stirred at room temperature for 24 h, quenched with H2O, and then the pH was adjusted to ~7–8 with saturated NaHCO3. The mixture was extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure and purified with column chromatography (silica gel, DCM/MeOH/TEA = 10/1/0.1) to afford a pure product.
3-Benzoylpiperidin-1-ium Chloride (2a). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.97–7.95 (m, 2H), 7.58–7.55 (m, 1H), 7.49–7.45 (m, 2H), 3.64–3.46 (m, 1H), 3.27–3.24 (m, 3H), 3.10 (d, J = 12.3 Hz, 1H), 2.90 (dd, J = 12.4, 9.9 Hz, 1H), 2.71–2.69 (m, 1H), 2.04–2.02 (m, 1H), 1.84–1.56 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 202.4, 136.0, 133.1, 128.7, 128.3, 48.9, 46.3, 44.7, 28.0, 25.4. HRMS (+ESI) m/z calculated for [M + H]+ 190.1226, found 190.1230.
3-(4-Methylbenzoyl)piperidin-1-ium Chloride (2b). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.87 (d, J = 8.2 Hz, 2H), 7.32–7.23 (m, 2H), 3.74 (br, 2H), 3.67–3.56 (m, 2H), 3.29 (d, J = 12.2 Hz, 1H), 3.16 (d, J = 12.7 Hz, 1H), 2.94 (dd, J = 12.4, 10.2 Hz, 1H), 2.80–2.64 (m, 1H), 2.41 (s, 3H), 2.10–1.97 (m, 1H), 1.82–1.75 (m, 1H), 1.74–1.62 (m, 1H), 1.48 (t, J = 7.3 Hz, 1H). 13C-NMR (101 MHz, CDCl3): δ 201.4, 144.1, 133.2, 129.5, 128.5, 48.2, 45.8, 43.7, 27.8, 24.6, 21.6. HRMS (+ESI) m/z calculatedfor [M + H]+ 204.1383, found 204.1387.
3-(4-Fluorobenzoyl)piperidin-1-ium Chloride (2c). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.00 (dd, J = 8.7, 5.5 Hz, 2H), 7.17–7.13 (m, 2H), 3.63–3.45 (m, 1H), 3.34 (br, 2H), 3.26 (d, J = 12.1 Hz, 1H), 3.12 (d, J = 11.8 Hz, 1H), 2.96–2.82 (m, 1H), 2.72 (t, J = 9.6 Hz, 1H), 2.10–2.05 (m, 1H), 1.86–1.62 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 200.5, 166.8 (d, J = 253.0 Hz), 132.2 (d, J = 3.0 Hz), 131.0 (d, J = 9.0 Hz), 115.9 (d, J = 22.0 Hz), 48.6, 46.1, 44.3, 27.9, 25.0. HRMS (+ESI) m/z calculatedfor [M + H]+ 208.1132, found 208.1136.
3-(2-Methylbenzoyl)piperidin-1-ium Chloride (2d). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.63 (d, J = 7.8 Hz, 1H), 7.40–7.36 (m, 1H), 7.32–7.24 (m, 2H), 5.03 (br, 2H), 3.64–3.59 (m, 1H), 3.42 (dd, J = 12.4, 2.8 Hz, 1H), 3.27 (dt, J = 12.4, 3.6 Hz, 1H), 3.05–2.93 (m, 1H), 2.87–2.71 (m, 1H), 2.45 (s, 3H), 2.11–1.99 (m, 1H), 1.84 (tt, J = 7.2, 3.6 Hz, 2H), 1.66–1.51 (m, 1H). 13C-NMR (101 MHz, CDCl3): δ 204.9, 138.2, 136.8, 132.0, 131.4, 128.1, 125.8, 46.9, 45.4, 45.2, 26.9, 23.7, 21.0. HRMS (+ESI) m/z calculated for [M + H]+ 204.1383, found 204.1387.
3-(2-Naphthoyl)piperidin-1-ium Chloride (2e). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.55 (s, 1H), 8.09–7.97 (m, 2H), 7.95–7.85 (m, 2H), 7.64–7.55 (m, 2H), 4.29 (br, 2H), 3.94–3.82 (m, 1H), 3.44 (d, J = 11.7 Hz, 1H), 3.30–3.20 (m, 1H), 3.04 (dd, J = 12.3, 10.4 Hz, 1H), 2.90–2.75 (m, 1H), 2.18–2.09 (m, 1H), 1.95–1.84 (m, 2H), 1.80–1.73 (m, 1H). 13C-NMR (101 MHz, CDCl3): δ 201.3, 135.7, 132.8, 132.6, 130.1, 129.7, 128.7, 128.7, 127.8, 126.9, 124.0, 48.1, 45.7, 43.5, 27.7, 24.3. HRMS (+ESI) m/z calculated for [M + H]+ 240.1383, found 240.1387.
3-Pentanoylpiperidin-1-ium Chloride (2f). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 3.61–3.55 (m, 1H), 3.46 (t, J = 14.0 Hz, 2H), 3.14 (tt, J = 11.5, 3.4 Hz, 1H), 3.03–2.91 (m, 1H), 2.82 (td, J = 12.6, 3.3 Hz, 1H), 2.54–2.43 (m, 2H), 2.18 (d, J = 13.4 Hz, 1H), 2.07–2.04 (m, 1H), 2.00–1.85 (m, 1H), 1.63–1.40 (m, 4H), 1.36–1.30 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ 209.7, 45.3, 44.7, 43.9, 40.7, 25.9, 25.4, 22.3, 21.9, 13.8. HRMS (+ESI) m/z calculated for [M + H]+ 170.1539, found 170.1543.
3-Isobutyrylpiperidin-1-ium Chloride (2g). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 3.88 (br, 1H), 3.55–3.40 (m, 2H), 3.40–3.27 (m, 2H), 3.05–2.95 (m, 1H), 2.93–2.73 (m, 2H), 2.15–1.93 (m, 3H), 1.58–1.40 (m, 1H), 1.15–1.08 (m, 6H). 13C-NMR (101 MHz, CDCl3): δ 213.4, 44.9, 43.9, 43.3, 39.3, 25.8, 19.3, 18.6, 17.8. HRMS (+ESI) m/z calculated for [M + H]+ 156.1383, found 156.1386.
3-(Thiophene-2-carbonyl)piperidin-1-ium Chloride (2h). Yellow oil.1H-NMR (400 MHz, CDCl3): δ 7.82 (d, J = 3.8 Hz, 1H), 7.68 (d, J = 4.9 Hz, 1H), 7.19–7.14 (m, 1H), 3.55–3.44 (m, 1H), 3.33 (d, J = 12.0 Hz, 1H), 3.21–3.08 (m, 3H), 3.02–2.93 (m, 1H), 2.77 (t, J = 11.5 Hz, 1H), 2.10–2.07 (m, 1H), 1.91–1.67 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 194.7, 143.5, 134.1, 132.1, 128.3, 48.7, 46.0, 29.7, 28.0, 24.9. HRMS (+ESI) m/z calculated for [M + H]+ 196.0791, found 196.0794.
3-Benzoyl-5-phenethylpiperidin-1-ium Chloride (2i). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.03 (d, J = 7.3 Hz, 0.45H), 7.96 (d, J = 7.3 Hz, 0.92H), 7.70–7.40 (m, 4H), 7.28–7.02 (m, 5H), 4.29–4.15 (m, 1H), 4.03 (d, J = 4.2 Hz, 1H), 3.72–3.55 (m, 2H), 3.45–3.41 (m, 1H), 3.21–2.85 (m, 2H), 2.77–2.49 (m, 3H), 2.47–2.17 (m, 1H), 2.13–1.99 (m, 1H), 1.91–1.84 (m, 2H), 1.79–1.47 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 201.4, 199.0, 161.8, 159.2, 141.2, 140.7, 134.8, 134.3, 134.2, 133.9, 129.1, 129.0, 128.7, 128.7, 128.6, 128.5, 128.3, 128.2, 126.2, 48.7, 47.8, 45.4, 44.8, 37.2, 35.6, 33.9, 33.4, 33.1, 32.6, 31.1, 29.7, 29.7. HRMS (+ESI) m/z calculated for [M + H]+ 294.1852, found 294.1855.
3-Benzoyl-5-methylpiperidin-1-ium Chloride (2j). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.98 (d, J = 7.5 Hz, 1.5H), 7.93 (d, J = 7.5 Hz, 0.3H), 7.61–7.57 (m, 1H), 7.51–7.47 (m, 2H), 3.59–3.52 (m, 1H), 3.29 (t, J = 10.8 Hz, 1H), 3.09 (d, J = 12.8 Hz, 0.72H), 3.01 (d, J = 12.8 Hz, 0.24H), 2.74 (t, J = 11.7 Hz, 1H), 2.37 (dd, J = 12.9, 9.0 Hz, 0.18H), 2.25 (dd, J = 12.9, 9.0 Hz, 0.78H), 2.20–2.12 (m, 0.2H), 2.02 (d, J = 13.3 Hz, 0.91H), 1.77 (td, J = 11.2, 7.0 Hz, 0.94H), 1.69–1.60 (m, 0.31H), 1.39–1.22 (m, 2H), 0.91 (dd, J = 13.4, 6.6 Hz, 3H).13C-NMR (101 MHz, CDCl3): δ 201.8, 136.0, 133.2, 128.8, 128.3, 53.6, 53.0, 48.4, 47.4, 45.3, 40.4, 36.5, 34.8, 31.5, 29.3, 19.4, 18.8. HRMS (+ESI) m/z calculated for [M + H]+ 204.1383, found 204.1387.
3-Benzoyl-5-phenylpiperidin-1-ium Chloride (2k). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 8.02 (d, J = 7.4 Hz, 1.68H), 7.95 (d, J = 7.4 Hz, 0.32H), 7.61–7.57 (m, 1H), 7.51–7.47 (m, 2H), 7.37–7.19 (m, 5H), 4.43 (br, 2H), 4.06–3.90 (m, 1H), 3.62–3.46 (m, 1H), 3.44–3.41 (m, 0.78H), 3.35–3.33 (m, 0.28H), 3.25–3.12 (m, 1H), 3.05 (t, J = 12.0 Hz, 1H), 2.96–2.87 (m, 0.4H), 2.84 (t, J = 12.1 Hz, 0.76H), 2.31–2.28 (m, 1H), 2.03–1.85 (m, 1H). 13C-NMR (101 MHz, CDCl3): δ 200.5, 141.8, 141.8, 135.5, 135.4, 133.5, 133.4, 128.9, 128.8, 128.3, 128.4, 127.2, 127.1, 52.0, 51.6, 47.3, 46.5, 43.8, 41.7, 40.0, 38.6, 34.7, 33.1. HRMS (+ESI) m/z calculated for [M + H]+ 266.1539, found 266.1545.
3-Benzoyl-5-(4-methoxyphenyl)piperidin-1-ium Chloride (2l). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 8.00 (d, J = 7.3 Hz, 1.66H), 7.93 (d, J = 7.3 Hz, 0.38H), 7.61–7.57 (m, 1H), 7.54–7.44 (m, 2H), 7.18 (d, J = 8.6 Hz, 1.61H), 7.13 (d, J = 8.6 H, 0.39H), 6.88–6.84 (m, 2H), 3.80 (s, 2.3H), 3.79 (s, 0.57H), 3.72 (tt, J = 11.5, 3.4 Hz, 1H), 3.49 (d, J = 12.3 Hz, 0.24H), 3.38 (d, J = 12.3 Hz, 0.82H), 3.28–3.24 (m, 0.88H), 3.20–3.16 (m, 0.18H), 3.03 (dd, J = 13.6, 3.9 Hz, 0.26H), 2.95–2.87 (m, 1.52H), 2.79–2.65 (m, 2H), 2.62 (br, 2H), 2.35–2.32 (m, 0.31H), 2.26–2.17 (m, 0.81H), 2.01–1.84 (m, 1H). 13C-NMR (101 MHz, CDCl3): δ 203.9, 201.6, 158.4, 158.2, 136.0, 135.9, 135.8, 135.4, 133.2, 133.1, 128.8, 128.3, 128.1, 128.0, 114.0, 113.9, 55.3, 53.5, 53.1, 48.6, 47.2, 45.6, 42.4, 40.6, 38.5, 36.9, 35.1, 33.7. HRMS (+ESI) m/z calculated for [M + H]+ 296.1645, found 296.1647.
3-Benzoyl-5-(4-fluorophenyl)piperidin-1-ium Chloride (2m). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.04–7.97 (m, 1.39H), 7.97–7.90 (m, 0.49H), 7.62–7.57 (m, 1H), 7.52–7.47 (m, 2H), 7.23–7.16 (m, 2H), 7.03–6.96 (m, 2H), 3.76 (tt, J = 11.5, 3.6 Hz, 0.72H), 3.68–3.64 (m, 0.29H), 3.50 (d, J = 13.5 Hz, 0.27H), 3.41 (d, J = 12.4 Hz, 0.7H), 3.29–3.21 (m, 1H), 3.12–2.82 (m, 4H), 2.82–2.65 (m, 1H), 2.33 (d, J = 13.2 Hz, 0.28H), 2.26–2.18 (m, 0.81H), 2.17–2.08 (m, 0.24H), 2.02–1.84 (m, 0.75H). 13C-NMR (101 MHz, CDCl3): δ 203.6, 201.3, 161.7 (d, J = 243.0 Hz), 161.5 (d, J = 243.0 Hz), 139.3 (d, J = 3.0 Hz), 138.7 (d, J = 4.0 Hz), 135.8 (d, J = 8.0 Hz), 133.3 (d, J = 11.0 Hz), 128.8, 128.6, 128.5, 128.3, 115.4 (d, J = 21.0 Hz), 115.23 (d, J = 21.0 Hz),53.1, 52.8, 48.4, 47.1, 45.2, 42.3, 40.4, 38.5, 34.9, 33.6. HRMS (+ESI) m/z calculated for [M + H]+ 284.1445, found 284.1453.
3-Benzoyl-5-(naphthalen-1-yl)piperidin-1-ium Chloride (2n). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 8.23 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 7.4 Hz, 1.58H), 7.99 (d, J = 7.4 Hz, 0.65H), 7.89 (d, J = 8.0 Hz, 0.69H), 7.84 (d, J = 8.0 Hz, 0.4H), 7.76 (d, J = 8.0 Hz, 0.62H), 7.73 (d, J = 8.0 Hz, 0.33H) 7.65–7.36 (m, 7H), 3.98–3.60 (m, 3H), 3.81–3.42 (m, 1.45H), 3.15 (dd, J=13.6, 4.0 Hz, 0.46H), 3.08–2.97 (m, 1H), 2.83 (t, J = 11.7 Hz, 1H), 2.57 (d, J = 13.5 Hz, 0.45H), 2.38 (d, J = 13.2 Hz, 0.77H), 2.27–2.16 (m,1H), 2.13– 2.00 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 203.6, 201.3, 162.9, 162.7, 160.4, 160.3, 139.3, 138.8, 138.7, 135.8, 135.8, 133.3, 133.2, 128.8, 128.6, 128.5, 128.3, 115.5, 115.4, 115.3, 115.2, 53.1, 52.8, 48.4, 47.1, 45.2, 42.3, 40.4, 38.5, 34.9, 33.6. HRMS (+ESI) m/z calculated for [M + H]+ 316.1696, found 316.1701.
3-Benzoyl-5-(thiophen-2-yl)piperidin-1-ium Chloride (2o). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.01 (d, J = 7.3 Hz, 1.67H), 7.93 (d, J = 7.3 Hz, 0.28H), 7.61–7.57 (m, 1H), 7.51–7.47 (m, 2H), 7.31–7.25 (m, 1H), 7.04 (d, J = 1.7 Hz, 1H), 7.00 (dd, J = 5.0, 0.8 Hz, 1H), 4.03 (br, 2H), 3.91 (tt, J = 11.8, 3.3 Hz, 1H), 3.59–3.53 (m, 0.17H), 3.47 (d, J = 12.2 Hz, 2H), 3.38–3.31 (m, 0.24H), 3.29–3.22 (m, 0.9H), 3.13–3.05 (m, 0.35H), 3.02–2.96 (m, 0.89H), 2.93–2.87 (m, 0.22H), 2.77–2.72 (m, 1H), 2.66 (d, J = 9.3 Hz, 1H), 2.40–2.33 (m, 1H), 2.26–2.15 (m, 0.29H), 1.89–1.80 (m, 1H). 13C-NMR (101 MHz, CDCl3): δ 203.1, 200.7, 147.0, 146.1, 135.7, 133.4, 133.3, 128.9, 128.8, 128.4, 126.8, 126.8, 123.5, 123.3, 123.3, 53.2, 52.7, 47.9, 44.6, 40.3, 37.8, 36.0, 34.7, 34.2, 29.7. HRMS (+ESI) m/z calculated for [M + H]+ 272.1104, found 272.1110.
3-Benzoyl-5-(thiophen-3-yl)piperidin-1-ium Chloride (2p). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.02–7.99 (m, 1.64H), 7.95–7.90 (m, 0.33H), 7.62–7.57 (m, 1H), 7.55–7.46 (m, 2H), 7.30–7.28 (m, 1H), 7.06–6.98 (m, 2H), 3.78 (tt, J = 11.6, 3.4 Hz, 0.81H), 3.71–3.62 (m, 0.23H), 3.46–3.36 (m, 2H), 3.28 (br, 2H), 3.22–3.01 (m, 2H), 3.02–2.83 (m, 1H), 2.79–2.60 (m, 1H), 2.41–2.32 (m, 1H), 2.26–2.13 (m, 0.31H), 1.92–1.82 (m, 0.89H). 13C-NMR (101 MHz, CDCl3) δ203.2, 200.3, 143.4, 142.5, 135.4, 133.6, 133.5, 128.9, 128.9, 128.5, 128.4, 126.7, 126.4, 126.1, 125.9, 120.4, 120.1, 51.1, 50.9, 46.9, 46.4, 43.4, 39.8, 34.7, 34.1, 33.1, 29.7. HRMS (+ESI) m/z calculated for [M + H]+ 272.1104, found 272.1110.
5-Benzoyl-2-phenylpiperidin-1-ium Chloride (2q). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.09–8.02 (m, 1.33H), 7.99–7.94 (m, 0.64H), 7.73–7.64 (m, 0.73H), 7.64–7.55 (m, 1.42H), 7.55–7.48 (m, 2.52H), 7.47–7.44 (m, 1.47H), 7.39–7.34 (m, 2H), 3.88–3.80 (m, 0.36H), 3.79–3.70 (m, 1.41H), 3.61–3.56 (m, 0.59H), 3.48–3.36 (m, 0.75H), 3.21 (dd, J = 13.9, 4.3 Hz, 0.38H), 3.04 (t, J = 11.5 Hz, 0.75H), 2.65 (br, 2H), 2.18–2.11 (m, 1H), 2.02–1.96 (m, 1H), 1.87–1.82 (m, 1H). 13C-NMR (101 MHz, CDCl3): δ 203.7, 201.9, 136.0, 133.2, 133.1, 132.1, 132.1, 132.0, 128.8, 128.6, 128.5, 128.4, 128.3, 127.6, 127.4, 126.8, 126.6, 61.7, 60.0, 49.5, 47.5, 44.1, 39.5, 33.4, 29.7, 29.3, 28.6. HRMS (+ESI) m/z calculated for [M + H]+ 266.1539, found 266.1545.
5-(4-Methoxybenzoyl)-2-(4-methoxyphenyl)piperidin-1-ium Chloride (2r). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 7.97 (d, J = 8.2 Hz, 0.28H), 7.87 (d, J = 8.2 Hz, 1.92H), 7.32–7.28 (m, 4H), 7.16 (d, J = 7.9 Hz, 2.24H), 4.50 (br, 2H), 3.96–3.86 (m, 1H), 3.78–3.75 (m, 0.17H), 3.67–3.51 (m, 1.87H), 3.48–3.45 (m, 0.19H), 3.24 (dd, J = 13.4, 3.7 Hz, 0.93H), 3.05 (t, J = 11.7 Hz, 0.14H), 2.44 (s, 3.09H), 2.40 (s, 0.19H), 2.34 (s, 2.84H), 2.30 (s, 0.2H), 2.25–2.07 (m, 2H), 1.92–1.84 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 203.1, 144.2, 138.8, 137.3, 133.1, 129.5, 129.3, 128.6, 126.6, 59.2, 47.0, 39.0, 28.7, 26.5, 21.7, 21.1.
5-(4-(Trifluoromethyl)benzoyl)-2-(4-(trifluoromethyl)phenyl)piperidin-1-ium Chloride (2s). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.03 (d, J = 8.1 Hz, 2H), 7.77 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.1 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 3.87–3.71 (m, 1H), 3.60 (dt, J = 13.1, 2.1 Hz, 1H), 3.51–3.47 (m, 1H), 3.20 (dd, J = 13.2, 3.9 Hz, 1H), 2.41–2.24 (m, 1H), 2.14–1.95 (m, 1H), 1.89 (br, 2H), 1.86–1.79 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 202.6, 148.3, 139.2, 134.1 (q, J = 32.6 Hz), 129.3 (q, J = 32.3 Hz), 125.8 (q, J = 3.7 Hz), 125.4 (q, J = 3.8 Hz), 124.2(q, J = 272.7 Hz ), 123.6 (q, J = 273.7 Hz), 60.3, 48.1, 40.7, 30.1, 26.2. HRMS (+ESI) m/z calculated for [M + H]+ 402.1287, found 402.1309.
3-(Ethoxycarbonyl)piperidin-1-ium Chloride (2t) [23]. Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 4.13 (q,J = 7.1 Hz, 2H), 3.16 (dd, J = 12.4, 3.6 Hz, 1H), 2.93 (dt, J = 12.2, 3.9 Hz, 1H), 2.81 (dd, J = 12.4, 9.3 Hz, 1H), 2.72–2.57 (m, 1H), 2.47–2.40 (m, 1H), 2.06–1.94 (m, 2H), 1.75 (br, 2H), 1.71–1.59 (m, 2H), 1.53–1.38 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 174.3, 60.2, 48.5, 46.3, 42.4, 27.3, 25.40, 14.2.
3-(Ethoxycarbonyl)-5-methylpiperidin-1-ium Chloride (2u). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 4.34–4.11 (m, 2H), 3.77–3.65 (m, 1H), 3.60–3.54 (m, 1H), 3.47–3.32 (m, 1H), 3.21–3.10 (m, 1H), 3.04–2.92 (m, 0.67H), 2.84 (t, J = 12.6 Hz, 0.35H), 2.75–2.69 (m, 0.64H), 2.65 (d, J = 9.3 Hz, 0.24H), 2.26–2.14 (m, 0.70H), 2.11–2.06 (m, 1.34H), 1.64–1.53 (m, 0.7H), 1.51–1.47 (m, 0.29H), 1.33–1.25 (m, 3H), 1.08 (d, J = 7.8 Hz, 1.77H), 1.01 (d, J = 7.8 Hz). 13C-NMR (101 MHz, CDCl3): δ 172.2, 171.3, 61.9, 61.2, 49.6, 49.5, 44.3, 44.0, 38.7, 36.2, 34.3, 32.2, 25.5, 18.6, 18.3, 14.1, 14.1. HRMS (+ESI) m/z calculatedfor [M + H]+ 172.1332, found 172.1339.
3-(Ethoxycarbonyl)-5-phenylpiperidin-1-ium Chloride (2v). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.37–7.31 (m, 2H), 7.28–7.21 (m, 3H), 4.34–4.13 (m, 2H), 3.51 (d, J = 13.2 Hz, 0.74H), 3.43 (d, J = 13.2 Hz, 0.31H), 3.25–3.20 (m, 1H), 2.91–2.65 (m, 4H), 2.43 (d, J = 13.5 Hz, 0.86H), 2.33 (d, J = 13.5 Hz, 0.44H), 2.22 (br, 2H), 1.99–1.92 (ddd, J = 13.6, 9.6, 4.4 Hz, 0.86H), 1.86–1.77 (q, J = 12.6 Hz, 0.37H ), 1.34–1.28 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 174.5, 143.7, 128.6, 128.5, 127.1, 126.8, 126.5, 60.6, 53.0, 47.0, 34.4, 32.9, 29.7, 14.3, 14.2, 12.0. HRMS (+ESI) m/z calculated for [M + H]+ 234.1489, found 234.1493.
3-(Ethoxycarbonyl)-5-(4-methoxyphenyl)piperidin-1-ium Chloride (2w). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.18–7.12 (m, 2H), 6.91–6.84 (m, 2H), 4.36–4.09 (m, 2H), 3.81 (s, 3H), 3.50 (d, J = 13.2 Hz, 0.77H), 3.44 (d, J = 13.2 Hz, 0.32H), 3.21 (t, J = 13.5 Hz, 1H), 2.90–2.75 (m, 2H), 2.73 (br, 2H), 2.71–2.59 (m, 2H), 2.40 (d, J = 13.1 Hz, 0.83H), 2.31 (d, J = 13.1 Hz, 0.36H), 1.95–1.87 (ddd, J = 13.6, 9.6, 4.4 Hz, 0.79H), 1.81–1.72 (q, J = 12.6 Hz, 0.34H), 1.34–1.25 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 174.4, 173.3, 158.4, 158.2, 135.7, 134.9, 128.0, 114.0, 113.9, 60.7, 60.6, 55.3, 53.0, 52.4, 47.4, 46.8, 39.6, 39.2, 34.5, 33.1, 29.7, 14.3, 14.2. HRMS (+ESI) m/z calculated for [M + H]+ 264.1594, found 264.1598.
3-(Ethoxycarbonyl)-5-(4-fluorophenyl)piperidin-1-ium Chloride (2x). Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.22–7.16 (m, 2H), 7.05–6.97 (m, 2H), 4.31–4.11 (m, 2H), 3.49 (d, J = 13.3 Hz, 0.7H), 3.43–3.35 (m, 0.33H), 3.16 (d, J = 11.7 Hz, 1H), 2.89–2.81 (m, 1H), 2.76–2.59 (m, 3H), 2.44–2.35 (m, 0.72H), 2.31–2.26 (m, 0.34H), 2.00 (br, 2H), 1.92–1.85 (ddd, J = 13.6, 9.6, 4.4 Hz, 0.84H), 1.81–1.72 (q, J = 12.6 Hz, 0.40H), 1.34–1.26 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 174.1, 172.8, 161.7 (d, J = 244.0 Hz), 161.6 (d, J = 243.0 Hz), 139.0 (d, J = 3.0 Hz), 138.0 (d, J = 3.0 Hz), 128.5 (d, J = 8.0 Hz), 128.4 (d, J = 8.0 Hz), 115.5 (d, J = 22.0 Hz), 115.4 (d, J = 21.0 Hz), 60.8, 52.7, 51.7, 46.8, 46.6, 41.9, 41.1, 39.4, 39.0, 34.2, 32.9, 29.7, 14.3, 14.2. HRMS (+ESI) m/z calculated for [M + H]+ 252.1394, found 252.1399.
3-(Benzyloxy)-5-(ethoxycarbonyl)piperidin-1-ium Chloride (2y). Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 7.55–7.30 (m, 5H), 4.91 (br, 2H), 4.70–4.62 (m, 0.62H), 4.64–4.54 (m, 1.62H), 4.24–4.04 (m, 2H), 3.94–3.80 (m, 1H), 3.62–3.33 (m, 2H), 3.21–3.02 (m, 1H), 3.03–2.78 (m, 2H), 2.45–2.41 (m, 0.56H), 2.34–2.31 (m, 0.52H), 1.92–1.79 (m, 0.56H), 1.79–1.66 (m, 0.49H), 1.28–1.23 (m, 3H). 13C-NMR (101 MHz, CDCl3): δ 172.3, 171.8, 137.6, 128.5, 128.5, 127.9, 127.9, 127.8, 127.6, 71.1, 70.7, 70.6, 68.5, 61.4, 61.2, 47.6, 46.8, 45.4, 44.9, 37.5, 35.6, 31.6, 30.2, 14.1, 14.1. HRMS (+ESI) m/z calculated for [M + H]+ 264.1594, found 264.1598.
1,2,3,4-Tetrahydroquinoxaline (4a) [29]. Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 6.63–6.61 (m, 2H), 6.56–6.47 (m, 2H), 3.45 (s, 4H). 13C-NMR (101 MHz, CDCl3) δ 133.7, 118.8, 114.7, 41.4.
2-Phenyl-1,2,3,4-tetrahydroquinoxaline (4b) [40]. White solid. 1H-NMR (400 MHz, CDCl3): δ 7.50–7.39 (m, 4H), 7.38–7.34 (m, 1H), 6.70–6.67 (m, 2H), 6.64 –6.61 (m, 2H), 4.52 (dd, J = 8.2, 3.1 Hz, 1H), 3.92 (br, 2H), 3.50 (dd, J = 11.0, 3.1 Hz, 1H), 3.37 (dd, J = 11.0, 8.2 Hz, 1H). 13C-NMR (101 MHz, CDCl3) δ 141.9, 134.2, 132.9, 128.7, 127.9, 127.0, 118.9, 118.8, 114.7, 114.5, 54.8, 49.2.
2-(4-Chlorophenyl)-4-methyl-3,4-dihydroquinazoline (4c). Yellow solid. 1H-NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.27–7.23 (m, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.13–7.09 (m, 1H), 7.04 (d, J = 7.4 Hz, 1H), 4.91 (q, J = 6.5 Hz, 1H), 1.54 (d, J = 6.5 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ 152.9, 141.0, 136.7, 133.9, 128.8, 128.1, 128.0, 125.8, 125.1, 125.0, 123.3, 49.3, 25.6.
4-(4-Chlorophenyl)-1-methyl-1,2-dihydrophthalazine (4d). Yellow solid. 1H-NMR (400 MHz, CDCl3): δ 7.59 (d, J = 8.4 Hz, 2H), 7.48–7.42 (m, 3H), 7.34–7.27 (m, 1H), 7.25–7.22 (m, 2H), 6.07 (br, 1H), 4.41 (q, J = 6.4 Hz, 1H), 1.55 (d, J = 6.5 Hz, 3H). 13C-NMR (101 MHz, CDCl3): δ 148.1, 137.2, 135.0, 134.1, 130.7, 129.7, 128.6, 127.3, 125.3, 125.0, 123.7, 49.9, 18.1.
1,2,3,4-Tetrahydroquinoline (4e) [41]. Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.08–7.03 (m, 2H), 6.72–6.68 (m, 1H), 6.55 (dd, J = 7.8, 0.6 Hz, 1H), 3.84 (br, 1H), 3.42–3.32 (m, 2H), 2.85 (t, J = 6.4 Hz, 2H), 2.08–1.97 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ 144.9, 129.6, 126.8, 121.5, 117.0, 114.3, 42.1, 27.1, 22.3.
1,2,3,4-Tetrahydroisoquinolin-2-ium Chloride (4f) [41]. Colorless oil. 1H-NMR (400 MHz, CDCl3): δ 7.27–7.18 (m, 2H), 7.18–7.13 (m, 1H), 7.13–7.07 (m, 1H), 5.47 (br, 2H), 4.27 (s, 2H), 3.38 (t, J = 6.1 Hz, 2H), 3.08 (t, J = 6.1 Hz, 2H). 13C-NMR (101 MHz, CDCl3) δ 136.1, 134.9, 129.4, 126.3, 126.0, 125.8, 48.4, 44.0, 29.3.
1,2,3,4-Tetrahydro-1,5-naphthyridine (4g) [42]. Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 7.88 (d, J = 4.5 Hz, 1H), 6.91 (dd, J = 8.0, 4.7 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 3.39–3.24 (m, 2H), 2.96 (t, J = 6.5 Hz, 2H), 2.09–2.02 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ 151.2, 137.9, 124.4, 121.9, 120.2, 41.5, 30.3, 21.8.
1,2,3,4-Tetrahydro-1,10-phenanthroline (4h) [43]. Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 8.71 (d, J = 3.1 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.32 (dd, J = 8.2, 4.2 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 7.00 (d, J = 8.2 Hz, 1H), 5.95 (s, 1H), 3.60–3.52 (m, 2H), 2.95 (t, J = 6.3 Hz, 2H), 2.17–2.04 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ 147.0, 140.7, 137.5, 135.9, 129.1, 127.4, 120.6, 116.6, 113.1, 41.3, 27.1, 21.8.
Ethyl 1,4,5,6-tetrahydropyridine-3-carboxylate (intermediate C) [12]. Yellow oil. 1H-NMR (400 MHz, CDCl3): δ 7.48 (d, J = 6.1 Hz, 1H), 4.45 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.27–3.15 (m, 2H), 2.34 (t, J = 6.2 Hz, 2H), 1.82 (dt, J = 11.9, 6.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H).

3.2. The Stereochemical Assignment of Disubstituted Piperidines

2v (41.2 mg, 0.15 mmol) and l-bromopropane (30.1 mg, 0.23 mmol) were refluxed in absolute ethanol (2 mL) with sodium bicarbonate (47.7 mg, 0.45 mol) for 18 h. The mixture was filtered through a pad of Celite. The inorganic salts were washed with several portions of fresh ethanol. The combined filtrates were evaporated in vacuo and the residue was purified by flash column chromatography to obtain compounds 5 (20.2 mg, 0.07 mmol, 46.5%) and 6 (5.4 mg, 0.02 mmol, 13.3%).
trans-Ethyl 1-butyl-5-phenylpiperidine-3-carboxylate (5) [39]. Yellow oil. 1H-NMR (400 MHz, CDCl3) δ 7.30 (d, J = 4.8 Hz, 4H), 7.23–7.17 (m, 1H), 4.23–4.15 (m, 2H), 3.29 (d, J = 9.6 Hz, 1H), 3.16–3.09 (m, 1H), 2.87 (dd, J = 11.4, 4.0 Hz 1H), 2.78–2.68 (m, 1H), 2.46–2.11 (m, 5H), 1.69–1.62 (m, 1H), 1.57–1.38 (m, 2H), 1.38 (m, 5H), 0.91 (t, J = 7.3 Hz, 3H).
cis-Ethyl 1-butyl-5-phenylpiperidine-3-carboxylate (6) [39]. Yellow oil. 1H-NMR (400 MHz, CDCl3) δ 7.40–7.30 (m, 2H), 7.24–7.19 (m, 3H),4.16 (q, J = 7.6 Hz, 1H), 3.26 (dt, J = 11.8 Hz, 1.6 Hz 1H), 3.04 (dt, J = 11.8 Hz, 1.6 Hz 1H), 2.95–2.82 (m, 1H), 2.82–2.68 (m, 1H), 2.42 (t, J = 7.2 Hz, 2H), 2.24 (d, J = 12.6 Hz, 1H), 2.05 (t, J = 11.3 Hz, 1H), 1.97 (t, J = 10.8 Hz, 1H), 1.64 (q, J = 12.3 Hz, 1H), 1.57–1.44 (m, 2H), 1.39–1.31 (m, 2H), 1.26 (t, J = 7.4 Hz, 3H), 0.94 (t, J = 7.3 Hz, 1H).

4. Conclusions

In conclusion, we have developed a HMPA-catalyzed metal-free transfer hydrogenation method for the reduction of pyridines. The functional group tolerance of this method provides an easy access method to various piperidines with ester or ketone groups at the C-3 position. The suitability of the method for the reduction of other N-heteroarenes has also been demonstrated. Efforts to extend the application of chiral HMPA derivatives in metal free pyridine reduction with HSiCl3 are currently underway.

Supplementary Materials

The following are available online: General experimental procedures, substrates, product characterization data, 1H- and 13C-NMR spectra substrates and NMR spectra.

Author Contributions

Y.F. performed the experiments and analyzed the results. J.S. conceived and designed the experiments and wrote the paper.

Funding

We are grateful for financial support from the National Natural Science Foundation of China (Project No. 21402185).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Källström, S.; Leino, R. Synthesis of pharmaceutically active compounds containing a disubstituted piperidine framework. Bioorg. Med. Chem. 2008, 16, 601–635. [Google Scholar] [CrossRef]
  2. Cadu, A.; Upadhyay, P.K.; Andersson, P.G. Iridium-Catalyzed Asymmetric Hydrogenation of Substituted Pyridines. Asian J. Org. Chem. 2013, 2, 1061–1065. [Google Scholar] [CrossRef] [Green Version]
  3. Chang, M.; Huang, Y.; Liu, S.; Chen, Y.; Krska, S.W.; Davies, I.W.; Zhang, X. Asymmetric Hydrogenation of Pyridinium Salts with an Iridium Phosphole Catalyst. Angew. Chem. Int. Ed. 2014, 53, 12761–12764. [Google Scholar] [CrossRef] [PubMed]
  4. Chen, M.-W.; Ye, Z.-S.; Chen, Z.-P.; Wu, B.; Zhou, Y.-G. Enantioselective synthesis of trifluoromethyl substituted piperidines with multiple stereogenic centers via hydrogenation of pyridinium hydrochlorides. Org. Chem. Front. 2015, 2, 586–589. [Google Scholar] [CrossRef]
  5. Glorius, F. Asymmetric hydrogenation of aromatic compounds. Org. Biomol. Chem. 2005, 3, 4171–4175. [Google Scholar] [CrossRef] [PubMed]
  6. Glorius, F.; Spielkamp, N.; Holle, S.; Goddard, R.; Lehmann, C.W. Efficient Asymmetric Hydrogenation of Pyridines. Angew. Chem. Int. Ed. 2004, 43, 2850–2852. [Google Scholar] [CrossRef] [PubMed]
  7. Huang, W.-X.; Wu, B.; Gao, X.; Chen, M.-W.; Wang, B.; Zhou, Y.-G. Iridium-Catalyzed Selective Hydrogenation of 3-Hydroxypyridinium Salts: A Facile Synthesis of Piperidin-3-ones. Org. Lett. 2015, 17, 1640–1643. [Google Scholar] [CrossRef]
  8. Huang, W.-X.; Yu, C.-B.; Ji, Y.; Liu, L.-J.; Zhou, Y.-G. Iridium-Catalyzed Asymmetric Hydrogenation of Heteroaromatics Bearing a Hydroxyl Group, 3-Hydroxypyridinium Salts. ACS Catal. 2016, 6, 2368–2371. [Google Scholar] [CrossRef]
  9. Iimuro, A.; Higashida, K.; Kita, Y.; Mashima, K. Asymmetric Hydrogenation of 3-Amido-2-arylpyridinium Salts by Triply Chloride-Bridged Dinuclear Iridium Complexes Bearing Enantiopure Diphosphine Ligands: Synthesis of Neurokinin-1 Receptor Antagonist Derivatives. Adv. Synth. Catal. 2016, 358, 1929–1933. [Google Scholar] [CrossRef]
  10. Karakulina, A.; Gopakumar, A.; Akçok, İ.; Roulier, B.L.; LaGrange, T.; Katsyuba, S.A.; Das, S.; Dyson, P.J. A Rhodium Nanoparticle–Lewis Acidic Ionic Liquid Catalyst for the Chemoselective Reduction of Heteroarenes. Angew. Chem. Int. Ed. 2016, 55, 292–296. [Google Scholar] [CrossRef]
  11. Legault, C.Y.; Charette, A.B. Catalytic Asymmetric Hydrogenation of N-Iminopyridinium Ylides: Expedient Approach to Enantioenriched Substituted Piperidine Derivatives. J. Am. Chem. Soc. 2005, 127, 8966–8967. [Google Scholar] [CrossRef] [PubMed]
  12. Lei, A.; Chen, M.; He, M.; Zhang, X. Asymmetric Hydrogenation of Pyridines: Enantioselective Synthesis of Nipecotic Acid Derivatives. Eur. J. Org. Chem. 2006, 2006, 4343–4347. [Google Scholar] [CrossRef]
  13. Oshima, K.; Ohmura, T.; Suginome, M. Regioselective Synthesis of 1,2-Dihydropyridines by Rhodium-Catalyzed Hydroboration of Pyridines. J. Am. Chem. Soc. 2012, 134, 3699–3702. [Google Scholar] [CrossRef] [PubMed]
  14. Renom-Carrasco, M.; Gajewski, P.; Pignataro, L.; delries, J.G.; Piarulli, U.; Gennari, C.; Lefort, L. A Mixed Ligand Approach for the Asymmetric Hydrogenation of 2-Substituted Pyridinium Salts. Adv. Synth. Catal. 2016, 358, 2589–2593. [Google Scholar] [CrossRef]
  15. Tang, W.; Sun, Y.; Lijin, X.; Wang, T.; Qinghua, F.; Lam, K.-H.; Chan, A.S. Highly efficient and enantioselective hydrogenation of quinolines and pyridines with Ir-Difluorphos catalyst. Org. Biomol. Chem. 2010, 8, 3464–3471. [Google Scholar] [CrossRef] [PubMed]
  16. Tang, W.-J.; Tan, J.; Xu, L.-J.; Lam, K.-H.; Fan, Q.-H.; Chan ASC. Highly Enantioselective Hydrogenation of Quinoline and Pyridine Derivatives with Iridium-(P-Phos) Catalyst. Adv. Synth. Catal. 2010, 352, 1055–1062. [Google Scholar] [CrossRef]
  17. Wu, J.; Tang, W.; Pettman, A.; Xiao, J. Efficient and Chemoselective Reduction of Pyridines to Tetrahydropyridines and Piperidines via Rhodium-Catalyzed Transfer Hydrogenation. Adv. Synth. Catal. 2012, 355, 35–40. [Google Scholar] [CrossRef]
  18. Ye, Z.-S.; Chen, M.-W.; Chen, Q.-A.; Shi, L.; Duan, Y.; Zhou, Y.-G. Iridium-Catalyzed Asymmetric Hydrogenation of Pyridinium Salts. Angew. Chem. Int. Ed. 2012, 51, 10181–10184. [Google Scholar] [CrossRef]
  19. Zheng, C.; You, S.-L. Transfer hydrogenation with Hantzsch esters and related organic hydride donors. Chem. Soc. Rev. 2012, 41, 2498–2518. [Google Scholar] [CrossRef]
  20. Rossi, S.; Benaglia, M.; Massolo, E.; Raimondi, L. Organocatalytic strategies for enantioselective metal-free reductions. Catal. Sci. Technol 2014, 4, 2708–2723. [Google Scholar] [CrossRef] [Green Version]
  21. Zhou, Y.-G. Asymmetric Hydrogenation of Heteroaromatic Compounds. Acc. Chem. Res. 2007, 40, 1357–1366. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Wang, D.-S.; Chen, Q.-A.; Lu, S.-M.; Zhou, Y.-G. Asymmetric Hydrogenation of Heteroarenes and Arenes. Chem. Rev. 2012, 112, 2557–2590. [Google Scholar] [CrossRef] [PubMed]
  23. Irfan, M.; Petricci, E.; Glasnov, T.N.; Taddei, M.; Kappe, C.O. Continuous Flow Hydrogenation of Functionalized Pyridines. Eur. J. Org. Chem. 2009, 2009, 1327–1334. [Google Scholar] [CrossRef]
  24. Miyamura, H.; Suzuki, A.; Yasukawa, T.; Kobayashi, S. Polysilane-Immobilized Rh–Pt Bimetallic Nanoparticles as Powerful Arene Hydrogenation Catalysts: Synthesis, Reactions under Batch and Flow Conditions and Reaction Mechanism. J. Am. Chem. Soc. 2018, 140, 11325–11334. [Google Scholar] [CrossRef] [PubMed]
  25. Mahdi, T.; del Castillo, J.N.; Stephan, D.W. Metal-Free Hydrogenation of N-Based Heterocycles. Organometallics 2013, 32, 1971–1978. [Google Scholar] [CrossRef]
  26. Liu, Y.; Du, H. Metal-Free Borane-Catalyzed Highly Stereoselective Hydrogenation of Pyridines. J. Am. Chem. Soc. 2013, 135, 12968–12971. [Google Scholar] [CrossRef]
  27. Zhou, Q.; Zhang, L.; Meng, W.; Feng, X.; Yang, J.; Du, H. Borane-Catalyzed Transfer Hydrogenations of Pyridines with Ammonia Borane. Org. Lett. 2016, 18, 5189–5191. [Google Scholar] [CrossRef]
  28. Gandhamsetty, N.; Park, S.; Chang, S. Selective Silylative Reduction of Pyridines Leading to Structurally Diverse Azacyclic Compounds with the Formation of sp3 C–Si Bonds. J. Am. Chem. Soc. 2015, 137, 15176–15184. [Google Scholar] [CrossRef]
  29. Liu, Z.-Y.; Wen, Z.-H.; Wang, X.-C. B(C6F5)3-Catalyzed Cascade Reduction of Pyridines. Angew. Chem. Int. Ed. 2017, 56, 5817–5820. [Google Scholar] [CrossRef]
  30. Rueping, M.; Antonchick, A.P. Organocatalytic Enantioselective Reduction of Pyridines. Angew. Chem. Int. Ed. 2007, 46, 4562–4565. [Google Scholar] [CrossRef]
  31. Malkov, A.V.; Vranková, K.; Stončius, S.; Kočovský, P. Asymmetric Reduction of Imines with Trichlorosilane, Catalyzed by Sigamide, an Amino Acid-Derived Formamide: Scope and Limitations. J. Org. Chem. 2009, 74, 5839–5849. [Google Scholar] [CrossRef] [PubMed]
  32. Guizzetti, S.; Benaglia, M. Trichlorosilane-Mediated Stereoselective Reduction of C=N Bonds. Eur. J. Org. Chem. 2010, 2010, 5529–5541. [Google Scholar] [CrossRef]
  33. Jones, S.; Zhao, P. Evaluating dynamic kinetic resolution strategies in the asymmetric hydrosilylation of cyclic ketimines. Tetrahedron Asymmetry 2014, 25, 238–244. [Google Scholar] [CrossRef]
  34. Orlandi, M.; Tosi, F.; Bonsignore, M.; Benaglia, M. Metal-Free Reduction of Aromatic and Aliphatic Nitro Compounds to Amines: A HSiCl3-Mediated Reaction of Wide General Applicability. Org. Lett. 2015, 17, 3941–3943. [Google Scholar] [CrossRef] [PubMed]
  35. Hu, X.-Y.; Zhang, M.-M.; Shu, C.; Zhang, Y.-H.; Liao, L.-H.; Yuan, W.-C.; Zhang, X.-M. Enantioselective Lewis-Base-Catalyzed Asymmetric Hydrosilylation of Substituted Benzophenone N-Aryl Imines: Efficient Synthesis of Chiral (Diarylmethyl)amines. Adv. Synth. Catal. 2014, 356, 3539–3544. [Google Scholar] [CrossRef]
  36. Barrulas, P.C.; Genoni, A.; Benaglia, M.; Burke, A.J. Cinchona-Derived Picolinamides: Effective Organocatalysts for Stereoselective Imine Hydrosilylation. Eur. J. Org. Chem. 2014, 2014, 7339–7342. [Google Scholar] [CrossRef] [Green Version]
  37. Warner, C.J.A.; Reeder, A.T.; Jones, S. P-Chiral phosphine oxide catalysed reduction of prochiral ketimines using trichlorosilane. Tetrahedron Asymmetry 2016, 27, 136–141. [Google Scholar] [CrossRef] [Green Version]
  38. Ye, J.; Wang, C.; Chen, L.; Wu, X.; Zhou, L.; Sun, J. Chiral Lewis Base-Catalyzed, Enantioselective Reduction of Unprotected β-Enamino Esters with Trichlorosilane. Adv. Synth. Catal. 2016, 358, 1042–1047. [Google Scholar] [CrossRef]
  39. Kippo, T.; Hamaoka, K.; Ueda, M.; Fukuyama, T.; Ryu, I. Bromoallylation of Alkenes Leading to 4-Alkenyl Bromides Based on Trapping of β-Bromoalkyl Radicals. Org. Lett. 2017, 19, 5198–5200. [Google Scholar] [CrossRef]
  40. Zhang, Y.; Zhu, J.; Xia, Y.-T.; Sun, X.-T.; Wu, L. Efficient Hydrogenation of Nitrogen Heterocycles Catalyzed by Carbon-Metal Covalent Bonds-Stabilized Palladium Nanoparticles: Synergistic Effects of Particle Size and Water. Adv. Synth. Catal. 2016, 358, 3039–3045. [Google Scholar] [CrossRef]
  41. Laval, S.; Dayoub, W.; Pehlivan, L.; Métay, E.; Favre-Reguillon, A.; Delbrayelle, D.; Mignani, G.; Lemaire, M. Straightforward access to cyclic amines by dinitriles reduction. Tetrahedron 2014, 70, 975–983. [Google Scholar] [CrossRef]
  42. Xuan, Q.; Song, Q. Diboron-Assisted Palladium-Catalyzed Transfer Hydrogenation of N-Heteroaromatics with Water as Hydrogen Donor and Solvent. Org. Lett. 2016, 18, 4250–4253. [Google Scholar] [CrossRef] [PubMed]
  43. Eisenberger, P.; Bestvater, B.P.; Keske, E.C.; Crudden, C.M. Hydrogenations at Room Temperature and Atmospheric Pressure with Mesoionic Carbene-Stabilized Borenium Catalysts. Angew. Chem. Int. Ed. 2015, 54, 1433–7851. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 1a, 1o and 1p are available from the authors.
Molecules 24 00401 g001 550
Figure 1. Selected examples for the synthesis of piperidines through the catalytic reduction of pyridines.
Figure 1. Selected examples for the synthesis of piperidines through the catalytic reduction of pyridines.
Molecules 24 00401 g001
Molecules 24 00401 g002 550
Figure 2. Substrate scope of the HMPA-catalyzed reduction of pyridines.
Figure 2. Substrate scope of the HMPA-catalyzed reduction of pyridines.
Molecules 24 00401 g002
Molecules 24 00401 g003 550
Figure 3. Substrate scope of the HMPA-catalyzed reduction of N-heteroarenes.
Figure 3. Substrate scope of the HMPA-catalyzed reduction of N-heteroarenes.
Molecules 24 00401 g003
Molecules 24 00401 g004 550
Figure 4. 1H-NMR spectra for mechanism studies.
Figure 4. 1H-NMR spectra for mechanism studies.
Molecules 24 00401 g004
Molecules 24 00401 g005 550
Figure 5. Proposed mechanism of HMPA-catalyzed reduction of ethyl nicotinate with HSiCl3.
Figure 5. Proposed mechanism of HMPA-catalyzed reduction of ethyl nicotinate with HSiCl3.
Molecules 24 00401 g005
Molecules 24 00401 g006 550
Figure 6. The gram-scale reaction of 1t.
Figure 6. The gram-scale reaction of 1t.
Molecules 24 00401 g006
Table
Table 1. Optimization of reaction conditions a.
Table 1. Optimization of reaction conditions a.
Molecules 24 00401 i001
EntrySolventLB (Equiv.)Temp (°C)Yield (%) b
1DCMHMPA (0.2)049.0
2DCMDMF (0.2)0trace
3DCMPOPh3 (0.2)037.0
4DCMHMPA (0.2)−1038.0
5DCMHMPA (0.2)2582.0
6THFHMPA (0.2)2564.0
7CHCl3HMPA (0.2)2576.0
8CCl4HMPA (0.2)25trace
9DCEHMPA (0.2)2577.0
10tolueneHMPA (0.2)25trace
11MeCNHMPA (0.2)25trace
12 cDCMHMPA (0.2)2560.0
13 dDCMHMPA (0.2)2581.0
14 eDCMHMPA (0.2)2586.0
15 fDCMHMPA (0.2)2596.0
16 fDCMHMPA (0.1)2582.0
17 fDCMHMPA (0.05)2554.0
a Unless otherwise specified, all reactions were performed with pyridines (0.1 mmol), HMPA and HSiCl3 (0.6 mmol) in solvent (1 mL) for 12 h. b Isolated yield. c HSiCl3 (0.4 mmol). d HSiCl3 (0.5 mmol). e HSiCl3 (0.8 mmol). f Reaction time is 24 h. hexamethylphosphoramide (HMPA).

Share and Cite

MDPI and ACS Style

Fu, Y.; Sun, J. HMPA-Catalyzed Transfer Hydrogenation of 3-Carbonyl Pyridines and Other N-Heteroarenes with Trichlorosilane. Molecules 2019, 24, 401. https://doi.org/10.3390/molecules24030401

AMA Style

Fu Y, Sun J. HMPA-Catalyzed Transfer Hydrogenation of 3-Carbonyl Pyridines and Other N-Heteroarenes with Trichlorosilane. Molecules. 2019; 24(3):401. https://doi.org/10.3390/molecules24030401

Chicago/Turabian Style

Fu, Yun, and Jian Sun. 2019. "HMPA-Catalyzed Transfer Hydrogenation of 3-Carbonyl Pyridines and Other N-Heteroarenes with Trichlorosilane" Molecules 24, no. 3: 401. https://doi.org/10.3390/molecules24030401

APA Style

Fu, Y., & Sun, J. (2019). HMPA-Catalyzed Transfer Hydrogenation of 3-Carbonyl Pyridines and Other N-Heteroarenes with Trichlorosilane. Molecules, 24(3), 401. https://doi.org/10.3390/molecules24030401

Article Metrics

Back to TopTop